Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

12.09.2022

1 Ann Intern Med
2 Br J Anaesth
4 Clin Infect Dis
3 Int J Infect Dis
1 Intensive Care Med
7 J Infect
13 J Med Virol
1 J Virol
1 JAMA
3 Lancet
6 Lancet Infect Dis
1 Life Sci
1 MMWR Morb Mortal Wkly Rep
9 N Engl J Med
5 Nature
1 Radiology
2 Science
1 Travel Med Infect Dis


    Ann Intern Med

  1. AGARWAL A, Martin GS
    In COVID-19 acute hypoxemia, awake prone positioning vs. usual care did not reduce intubation at 30 d.
    Ann Intern Med. 2022 Sep 6. doi: 10.7326/J22-0068.
    >> Share


    Br J Anaesth

  2. DAWSON J, Humphrey J, Samouelle J, Sherren PB, et al
    Impact of enhanced personal protective equipment on safety and logistics of pre-hospital emergency anaesthesia during the COVID-19 pandemic: a retrospective crossover study.
    Br J Anaesth. 2022 Jul 19. pii: S0007-0912(22)00368.
    >> Share

  3. BARNETT N, Leith D, Govind D, Ramnani V, et al
    Prevalence of pulmonary embolism and deep venous thrombosis during the COVID-19 pandemic in an intensive care unit cohort: a service evaluation.
    Br J Anaesth. 2022 Aug 11. pii: S0007-0912(22)00394.
    >> Share


    Clin Infect Dis

  4. KOJIMA N, Klausner JD
    Usage and awareness of antiviral medications for COVID-19 among individuals at risk for severe COVID-19, March 2021 to 1 August 2022.
    Clin Infect Dis. 2022 Sep 7. pii: 6693563. doi: 10.1093.
    >> Share

  5. MAGNUS MC, Haberg SE, Carlsen EO, Kwong JC, et al
    Pregnancy status at the time of COVID-19 vaccination and incidence of SARS-CoV-2 infection.
    Clin Infect Dis. 2022 Sep 8. pii: 6693880. doi: 10.1093.
    >> Share

  6. GOLAN Y, Campos JAS, Woolson R, Cilla D, et al
    Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial.
    Clin Infect Dis. 2022 Sep 6. pii: 6692456. doi: 10.1093.
    >> Share

  7. BHIMRAJ A, Morgan RL, Shumaker AH, Baden L, et al
    Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.
    Clin Infect Dis. 2022 Sep 5. pii: 6692369. doi: 10.1093.
    >> Share


    Int J Infect Dis

  8. ABROI A, Talas UG, Pauskar M, Shablinskaja A, et al
    SARS-CoV-2 dual infection of Delta and Omicron variants in an immunocompetent host - a case report.
    Int J Infect Dis. 2022 Sep 5. pii: S1201-9712(22)00497.
    >> Share

  9. LI YE, Wang S, Reiter RJ, Ren J, et al
    Clinical Cardiovascular Emergencies and the Cellular Basis of COVID-19 Vaccination: from a Dream to Reality?
    Int J Infect Dis. 2022 Sep 5. pii: S1201-9712(22)00498.
    >> Share

  10. LEE SS, Viboud C, Petersen E
    Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control.
    Int J Infect Dis. 2022;122:1002-1004.
    >> Share


    Intensive Care Med

  11. MEHTA P, Rosas IO, Singer M
    Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity.
    Intensive Care Med. 2022 Sep 8. pii: 10.1007/s00134-022-06877.
    >> Share


    J Infect

  12. WONG LSY, Loo EXL, Huang CH, Yap GC, et al
    Early seasonal coronavirus seroconversion did not produce cross-protective SARS-CoV-2 antibodies.
    J Infect. 2022 Sep 3. pii: S0163-4453(22)00515.
    >> Share

  13. COOPER DJ, Lear S, Watson L, Shaw A, et al
    A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital.
    J Infect. 2022 Sep 1. pii: S0163-4453(22)00514.
    >> Share

  14. YIN Y, Lin J, Yuan S, Tong S, et al
    The relationship between early isolation and the duration of viral shedding of mild and asymptomatic infection with SARS-CoV-2 Omicron BA.2 variant.
    J Infect. 2022 Sep 1. pii: S0163-4453(22)00520.
    >> Share

  15. SHI T, Dai M, Liu F, Hu J, et al
    Dynamics of immune responses to inactivated COVID-19 vaccination over 8 months in China.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00521.
    >> Share

  16. DIMEGLIO C, Tremeaux P, Herin F, Da-Silva I, et al
    Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00522.
    >> Share

  17. PATAPNYAN E, Ronen O
    Parallel reduction in the prevalence of Bell's palsy, idiopathic sudden sensorineural hearing loss and viral infection diseases during the COVID-19 pandemic.
    J Infect. 2022 Sep 2. pii: S0163-4453(22)00518.
    >> Share

  18. LAI CK, Lui GC, Wei Y, Chong KC, et al
    Remdesivir reduced upper respiratory tract SARS-CoV-2 viral RNA concentration in COVID-19 patients who developed pneumonitis.
    J Infect. 2022 Aug 31. pii: S0163-4453(22)00513.
    >> Share


    J Med Virol

  19. MARCHI L, Vidiri A, Fera EA, Pallottini M, et al
    SARS-CoV-2 IgG "heritage" in newborn: a credit of maternal natural infection.
    J Med Virol. 2022 Sep 7. doi: 10.1002/jmv.28133.
    >> Share

  20. CELIK E, Ozcan G, Vatansever C, Paerhati E, et al
    Alterations in Vaginal Microbiota among Pregnant Women with COVID-19.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28132.
    >> Share

  21. RZYMSKI P, Kasianchuk N, Sikora D, Poniedzialek B, et al
    COVID-19 Vaccinations and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28131.
    >> Share

  22. FAIZO AA, Qashqari FS, El-Kafrawy SA, Barasheed O, et al
    A Potential Association between Obesity and Reduced Effectiveness of COVID-19 Vaccine-Induced Neutralizing Humoral Immunity.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28130.
    >> Share

  23. WANG Q, Ye SB, Zhou ZJ, Li JY, et al
    Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28116.
    >> Share

  24. WANG C, Liu B, Zhang S, Huang N, et al
    Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: a world-wide review.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28118.
    >> Share

  25. YU T, Liu F, Yi N, Yin H, et al
    Evaluating agreement in different diagnosis methods is necessary.
    J Med Virol. 2022 Sep 2. doi: 10.1002/jmv.28117.
    >> Share

  26. WETTSTEIN L, Immenschuh P, Weil T, Conzelmann C, et al
    Native and activated antithrombin inhibits TMPRSS2 activity and SARS-CoV-2 infection.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28124.
    >> Share

  27. ARISH M, Qian W, Narasimhan H, Sun J, et al
    COVID-19 immunopathology: From acute diseases to chronic sequelae.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28122.
    >> Share

  28. NICOT F, Tremeaux P, Latour J, Nicolas J, et al
    WHOLE GENOME SEQUENCING OF SARS-CoV-2: COMPARISON OF TARGET CAPTURE AND AMPLICON SINGLE MOLECULAR REAL TIME SEQUENCING PROTOCOLS.
    J Med Virol. 2022 Sep 3. doi: 10.1002/jmv.28123.
    >> Share

  29. SCARPA F, Sanna D, Azzena I, Giovanetti M, et al
    On the SARS-CoV-2 BA.2.75 variant: a genetic and structural point of view.
    J Med Virol. 2022 Sep 4. doi: 10.1002/jmv.28119.
    >> Share

  30. AKASH S, Rahman MM, Islam MR, Sharma R, et al
    Emerging global concern of Langya Henipavirus: Pathogenicity, Virulence, Genomic features, and Future perspectives.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28127.
    >> Share

  31. ABDALLA M, El-Arabey AA, Gai Z
    Hypertension is still a moving target in the context of COVID-19 and post-acute COVID-19 syndrome.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28128.
    >> Share


    J Virol

  32. AO Z, Ouyang MJ, Olukitibi TA, Warner B, et al
    A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    J Virol. 2022 Sep 7:e0133722. doi: 10.1128/jvi.01337.
    >> Share


    JAMA

  33. ABBASI J
    The US Now Has a Research Plan for Long COVID-Is It Enough?
    JAMA. 2022;328:812-814.
    >> Share


    Lancet

  34. GORMAN EA, O'Kane CM, McAuley DF
    Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management.
    Lancet. 2022 Sep 2. pii: S0140-6736(22)01439.
    >> Share

  35. ZHANG Y, Wang Y, Ning G, He P, et al
    Protecting older people: a high priority during the COVID-19 pandemic.
    Lancet. 2022;400:729-730.
    >> Share

  36. THORNTON J
    New centre for pandemic therapeutics.
    Lancet. 2022;400:722.
    >> Share


    Lancet Infect Dis

  37. DONG E, Ratcliff J, Goyea TD, Katz A, et al
    The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned.
    Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00434.
    >> Share

  38. WELLS CR, Galvani AP
    Tackling the politicisation of COVID-19 data reporting through open access data sharing.
    Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00505.
    >> Share

  39. BILLARD MN, Bont LJ
    Quantifying the RSV immunity debt following COVID-19: a public health matter.
    Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00544.
    >> Share

  40. BARDSLEY M, Morbey RA, Hughes HE, Beck CR, et al
    Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study.
    Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00525.
    >> Share

  41. GEURTSVANKESSEL CH, de Vries RD
    Evaluating novel COVID-19 vaccines in the current chapter of the pandemic.
    Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00517.
    >> Share

  42. LAZARUS R, Querton B, Corbic Ramljak I, Dewasthaly S, et al
    Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
    Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00502.
    >> Share


    Life Sci

  43. BARTOLOMEO CS, Lemes RMR, Morais RL, Pereria GC, et al
    SARS-CoV-2 infection and replication kinetics in different human cell types: The role of autophagy, cellular metabolism and ACE2 expression.
    Life Sci. 2022 Sep 5:120930. doi: 10.1016/j.lfs.2022.120930.
    >> Share


    MMWR Morb Mortal Wkly Rep

  44. TASSETTO M, Garcia-Knight M, Anglin K, Lu S, et al
    Detection of Higher Cycle Threshold Values in Culturable SARS-CoV-2 Omicron BA.1 Sublineage Compared with Pre-Omicron Variant Specimens - San Francisco Bay Area, California, July 2021-March 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1151-1154.
    >> Share


    N Engl J Med

  45. ABDOOL KARIM SS, Devnarain N
    Time to Stop Using Ineffective Covid-19 Drugs.
    N Engl J Med. 2022;387:654-655.
    >> Share

  46. BRAMANTE CT, Huling JD, Tignanelli CJ, Buse JB, et al
    Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
    N Engl J Med. 2022;387:599-610.
    >> Share

  47. CHARNESS ME, Gupta K, Stack G, Strymish J, et al
    Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2206449.
    >> Share

  48. QU P, Faraone JN, Evans JP, Zheng YM, et al
    Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2210546.
    >> Share

  49. SULLIVAN DJ, Gebo KA, Hanley DF
    Convalescent Plasma for Covid-19. Reply.
    N Engl J Med. 2022;387:955-956.
    >> Share

  50. PANETH N
    Convalescent Plasma for Covid-19.
    N Engl J Med. 2022;387:955.
    >> Share

  51. JOYNER MJ, Pirofski LA
    Convalescent Plasma for Covid-19.
    N Engl J Med. 2022;387:955.
    >> Share

  52. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Rolling Out New Covid-19 Vaccines.
    N Engl J Med. 2022;387:e26.
    >> Share

  53. ANDERSON AS, Caubel P, Rusnak JM
    Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2205944.
    >> Share


    Nature

  54. WALTZ E
    China and India approve nasal COVID vaccines - are they a game changer?
    Nature. 2022 Sep 7. pii: 10.1038/d41586-022-02851.
    >> Share


  55. Lost trees, booster benefits - the week in infographics.
    Nature. 2022 Sep 7. pii: 10.1038/d41586-022-02844.
    >> Share

  56. LEWIS D
    What scientists have learnt from COVID lockdowns.
    Nature. 2022;609:236-239.
    >> Share

  57. LI Y, Watanabe E, Kawashima Y, Plichta DR, et al
    Identification of trypsin-degrading commensals in the large intestine.
    Nature. 2022 Sep 7. pii: 10.1038/s41586-022-05181.
    >> Share

  58. WALTZ E
    How nasal-spray vaccines could change the pandemic.
    Nature. 2022;609:240-242.
    >> Share


    Radiology

  59. POLYAKOV NJ, Som A, Mercaldo ND, Di Capua J, et al
    True-Positive Rate of RSNA Typical Chest CT Findings for COVID-19 Pneumonia in an Increasingly Vaccinated Population.
    Radiology. 2022 Sep 6:220680. doi: 10.1148/radiol.220680.
    >> Share


    Science

  60. PIERCE CA, Herold KC, Herold BC, Chou J, et al
    COVID-19 and children.
    Science. 2022;377:1144-1149.
    >> Share

  61. RICHARDS CM, Jabs S, Qiao W, Varanese LD, et al
    The human disease gene LYSET is essential for lysosomal enzyme transport and viral infection.
    Science. 2022 Sep 8:eabn5648. doi: 10.1126/science.abn5648.
    >> Share


    Travel Med Infect Dis

  62. CHU DT, Thi HV, Al-Tawfiq JA, Memish ZA, et al
    Children orphaned by COVID-19: A grim picture and the need of urgent actions.
    Travel Med Infect Dis. 2022 Sep 2:102446. doi: 10.1016/j.tmaid.2022.102446.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016